346 related articles for article (PubMed ID: 24014509)
1. Clinical trials in rare disease: challenges and opportunities.
Augustine EF; Adams HR; Mink JW
J Child Neurol; 2013 Sep; 28(9):1142-50. PubMed ID: 24014509
[TBL] [Abstract][Full Text] [Related]
2. Methodology of clinical research in rare diseases: development of a research program in juvenile neuronal ceroid lipofuscinosis (JNCL) via creation of a patient registry and collaboration with patient advocates.
de Blieck EA; Augustine EF; Marshall FJ; Adams H; Cialone J; Dure L; Kwon JM; Newhouse N; Rose K; Rothberg PG; Vierhile A; Mink JW;
Contemp Clin Trials; 2013 Jul; 35(2):48-54. PubMed ID: 23628560
[TBL] [Abstract][Full Text] [Related]
3. Funding resources for rare disease research.
Stehr F; Forkel M
Biochim Biophys Acta; 2013 Nov; 1832(11):1910-2. PubMed ID: 23608548
[TBL] [Abstract][Full Text] [Related]
4. A novel, hybrid, single- and multi-site clinical trial design for CLN3 disease, an ultra-rare lysosomal storage disorder.
Adams HR; Defendorf S; Vierhile A; Mink JW; Marshall FJ; Augustine EF
Clin Trials; 2019 Oct; 16(5):555-560. PubMed ID: 31184505
[TBL] [Abstract][Full Text] [Related]
5. Considerations for the treatment of infantile neuronal ceroid lipofuscinosis (infantile Batten disease).
Sands MS
J Child Neurol; 2013 Sep; 28(9):1151-8. PubMed ID: 24014510
[TBL] [Abstract][Full Text] [Related]
6. Pathogenesis and therapies for infantile neuronal ceroid lipofuscinosis (infantile CLN1 disease).
Hawkins-Salsbury JA; Cooper JD; Sands MS
Biochim Biophys Acta; 2013 Nov; 1832(11):1906-9. PubMed ID: 23747979
[TBL] [Abstract][Full Text] [Related]
7. Progress towards understanding the neurobiology of Batten disease or neuronal ceroid lipofuscinosis.
Cooper JD
Curr Opin Neurol; 2003 Apr; 16(2):121-8. PubMed ID: 12644737
[TBL] [Abstract][Full Text] [Related]
8. The neuronal ceroid-lipofuscinoses: a historical introduction.
Haltia M; Goebel HH
Biochim Biophys Acta; 2013 Nov; 1832(11):1795-800. PubMed ID: 22959893
[TBL] [Abstract][Full Text] [Related]
9. Gene Therapy for Rare Central Nervous System Diseases Comes to Age.
Aubourg P
Endocr Dev; 2016; 30():141-6. PubMed ID: 26684481
[TBL] [Abstract][Full Text] [Related]
10. Clinical challenges and future therapeutic approaches for neuronal ceroid lipofuscinosis.
Mole SE; Anderson G; Band HA; Berkovic SF; Cooper JD; Kleine Holthaus SM; McKay TR; Medina DL; Rahim AA; Schulz A; Smith AJ
Lancet Neurol; 2019 Jan; 18(1):107-116. PubMed ID: 30470609
[TBL] [Abstract][Full Text] [Related]
11. Gene Therapy Approaches to Treat the Neurodegeneration and Visual Failure in Neuronal Ceroid Lipofuscinoses.
Kleine Holthaus SM; Smith AJ; Mole SE; Ali RR
Adv Exp Med Biol; 2018; 1074():91-99. PubMed ID: 29721932
[TBL] [Abstract][Full Text] [Related]
12. Bioinformatic perspectives in the neuronal ceroid lipofuscinoses.
Kmoch S; Stránecký V; Emes RD; Mitchison HM
Biochim Biophys Acta; 2013 Nov; 1832(11):1831-41. PubMed ID: 23274885
[TBL] [Abstract][Full Text] [Related]
13. Mastering the dilemma of rare diseases.
Kohlschuetter A
Neuropediatrics; 2007 Feb; 38(1):1. PubMed ID: 17607595
[No Abstract] [Full Text] [Related]
14. Feasibility of gene therapy for late neuronal ceroid lipofuscinosis.
Sondhi D; Hackett NR; Apblett RL; Kaminsky SM; Pergolizzi RG; Crystal RG
Arch Neurol; 2001 Nov; 58(11):1793-8. PubMed ID: 11708986
[TBL] [Abstract][Full Text] [Related]
15. Progress in gene and cell therapies for the neuronal ceroid lipofuscinoses.
Donsante A; Boulis NM
Expert Opin Biol Ther; 2018 Jul; 18(7):755-764. PubMed ID: 29936867
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic landscape for Batten disease: current treatments and future prospects.
Johnson TB; Cain JT; White KA; Ramirez-Montealegre D; Pearce DA; Weimer JM
Nat Rev Neurol; 2019 Mar; 15(3):161-178. PubMed ID: 30783219
[TBL] [Abstract][Full Text] [Related]
17. Batten disease: clinical aspects, molecular mechanisms, translational science, and future directions.
Dolisca SB; Mehta M; Pearce DA; Mink JW; Maria BL
J Child Neurol; 2013 Sep; 28(9):1074-100. PubMed ID: 23838031
[TBL] [Abstract][Full Text] [Related]
18. Future perspectives: What lies ahead for Neuronal Ceroid Lipofuscinosis research?
Cooper JD; Mole SE
Biochim Biophys Acta Mol Basis Dis; 2020 Sep; 1866(9):165681. PubMed ID: 31926264
[TBL] [Abstract][Full Text] [Related]
19. Management Strategies for CLN2 Disease.
Williams RE; Adams HR; Blohm M; Cohen-Pfeffer JL; de Los Reyes E; Denecke J; Drago K; Fairhurst C; Frazier M; Guelbert N; Kiss S; Kofler A; Lawson JA; Lehwald L; Leung MA; Mikhaylova S; Mink JW; Nickel M; Shediac R; Sims K; Specchio N; Topcu M; von Löbbecke I; West A; Zernikow B; Schulz A
Pediatr Neurol; 2017 Apr; 69():102-112. PubMed ID: 28335910
[TBL] [Abstract][Full Text] [Related]
20. Use of model organisms for the study of neuronal ceroid lipofuscinosis.
Bond M; Holthaus SM; Tammen I; Tear G; Russell C
Biochim Biophys Acta; 2013 Nov; 1832(11):1842-65. PubMed ID: 23338040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
